Although the mechanism by which the TNF antagonist could potentially initiate the development of anti-factor VIII antibodies remains elusive, the efficacy of rituximab in refractory cases underscores the role of B cells in the pathogenesis of both RA and AHA [31,32]. The gene discussed is TNF; the disease is autoimmune hemolytic anemia.